Arch Dis Child Fetal Neonatal Ed 92:F498-F502 doi:10.1136/adc.2005.092734
  • Review
    • Review

Patent ductus arteriosus: lack of evidence for common treatments

  1. Carl L Bose,
  2. Matthew M Laughon
  1. Division of Neonatal-Perinatal Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
  1. Carl L Bose, Division of Neonatal-Perinatal Medicine, CB#7596, UNC Hospital, Chapel Hill, NC 27599-7596, USA; cbose{at}
  • Accepted 22 November 2006


Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decades of research, the question of whether the benefits of treatments to prevent ductal patency or promote closure outweigh the risks of these treatments remains unanswered. The authors rarely use treatments designed to close the PDA. This article reviews three considerations in support of this restrained approach: rates of spontaneous closure of the ductus arteriosus; adverse effect of persistent ductal patency; and benefits and risks of treatments for closure.


  • Competing interests: None.

  • Abbreviations:
    bronchopulmonary dysplasia
    chronic lung disease
    intraventricular haemorrhage
    necrotising enterocolitis
    patent ductus arteriosus

Responses to this article

Latest from Education & Practice

Latest from Education & Practice

Register for free content

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ADC Fetal & Neonatal.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article